Skip to main content
Journal cover image

Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report.

Publication ,  Journal Article
Oh, WK; George, DJ; Kaufman, DS; Moss, K; Smith, MR; Richie, JP; Kantoff, PW
Published in: Semin Oncol
August 2001

Effective treatment options for high-risk localized prostate cancer are limited. Patients at high risk for recurrence include those with biopsy Gleason scores of 8 to 10, prostate specific antigen (PSA) levels > 20 ng/mL, and clinical stage T3 disease. Docetaxel chemotherapy is active in hormone-refractory prostate cancer, either combined with estramustine or used as a single agent. To determine if systemic therapy can improve the outcome of radical prostatectomy in men with high-risk localized prostate cancer, we are undertaking a pilot phase II clinical trial of weekly docetaxel at 36 mg/m(2) for up to 6 months, followed by surgery. Patients are monitored with weekly visits, monthly digital rectal examinations, PSA measurement, and testosterone tests, and endorectal magnetic resonance imaging done at baseline, after two cycles, and again after six cycles. To date, 15 patients have been enrolled, and 70 cycles of chemotherapy have been administered. Toxicity has been mostly grade 1 in intensity, and fatigue has been the most common grade 2 toxicity reported. The primary endpoint of the trial is measurement of pathologic complete response rate, for which data are not yet available. Recruitment to the trial is ongoing.

Duke Scholars

Published In

Semin Oncol

DOI

ISSN

0093-7754

Publication Date

August 2001

Volume

28

Issue

4 Suppl 15

Start / End Page

40 / 44

Location

United States

Related Subject Headings

  • Taxoids
  • Prostatic Neoplasms
  • Prostatectomy
  • Pilot Projects
  • Paclitaxel
  • Oncology & Carcinogenesis
  • Neoadjuvant Therapy
  • Middle Aged
  • Male
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Oh, W. K., George, D. J., Kaufman, D. S., Moss, K., Smith, M. R., Richie, J. P., & Kantoff, P. W. (2001). Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report. Semin Oncol, 28(4 Suppl 15), 40–44. https://doi.org/10.1016/s0093-7754(01)90153-8
Oh, W. K., D. J. George, D. S. Kaufman, K. Moss, M. R. Smith, J. P. Richie, and P. W. Kantoff. “Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report.Semin Oncol 28, no. 4 Suppl 15 (August 2001): 40–44. https://doi.org/10.1016/s0093-7754(01)90153-8.
Oh WK, George DJ, Kaufman DS, Moss K, Smith MR, Richie JP, et al. Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report. Semin Oncol. 2001 Aug;28(4 Suppl 15):40–4.
Oh, W. K., et al. “Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report.Semin Oncol, vol. 28, no. 4 Suppl 15, Aug. 2001, pp. 40–44. Pubmed, doi:10.1016/s0093-7754(01)90153-8.
Oh WK, George DJ, Kaufman DS, Moss K, Smith MR, Richie JP, Kantoff PW. Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report. Semin Oncol. 2001 Aug;28(4 Suppl 15):40–44.
Journal cover image

Published In

Semin Oncol

DOI

ISSN

0093-7754

Publication Date

August 2001

Volume

28

Issue

4 Suppl 15

Start / End Page

40 / 44

Location

United States

Related Subject Headings

  • Taxoids
  • Prostatic Neoplasms
  • Prostatectomy
  • Pilot Projects
  • Paclitaxel
  • Oncology & Carcinogenesis
  • Neoadjuvant Therapy
  • Middle Aged
  • Male
  • Humans